Pharmaceuticals

FDA Grants Priority Review of Biologics License Application for Dupixent Add-on Maintenance for Treatment of Youth with Chronic Rhinosinusitis with Nasal Polyposis

bexib
By bexib 0 Min Read

Dupixent was previously approved for adults with chronic sinusitis with poorly controlled nasal polyposis.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Where have all the babies gone? Leaders, businessmen and economists sound the alarm about falling birth rates around the world
Next Article Overwhelming Support for Calves for a Cause at Canadian Dairy XPO – RealAgriculture
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

A look inside: Allies developing a multicloud hybrid strategy
Banking
2024 Holiday Shipping Deadline for the United States
International Shipping
Ecommerce taxes – How to stay ahead of the sales tax maze
Retail & E-commerce
Finastra breach: 3 security points
Banking